PsychonautWiki Archive

Mirtazapine: Difference between revisions

← Older editNewer edit →
>Blackhole
added brand name
>Larnaca
Add back in reverted edit about inverse agonism, this is consistent with the other wiki, pls discuss on talk page otherwise
(One intermediate revision by one other user not shown)
Line 1: Line 1:
{{SummarySheet}}
{{SummarySheet}}
{{SubstanceBox/Mirtazapine}}
{{SubstanceBox/Mirtazapine}}
'''Mirtazapine''' (trade name '''Remeron''' and '''Mirta TAD''', among others) is an [[psychoactive class::antidepressant]] substance of the [[Chemical class::piperazinoazepine]] class. At high doses, it has been reported to act as an atypical [[psychedelic]] and [[sedative]]. It is classified as a noradrenergic and specific serotonergic antidepressant (NaSSA).{{citation needed}}
'''Mirtazapine''' (trade name '''Remeron''', among others) is an [[psychoactive class::antidepressant]] substance of the [[Chemical class::piperazinoazepine]] class. At high doses, it has been reported to act as an atypical [[psychedelic]] and [[sedative]]. It is classified as a noradrenergic and specific serotonergic antidepressant (NaSSA).<ref>Roland A. Carlstedt (14 December 2009). ''Handbook of Integrative Clinical Psychology, Psychiatry, and Behavioral Medicine: Perspectives, Practices, and Research''. Springer Publishing Company. p. 290. [[ISBN (identifier)|ISBN]] [[Special:BookSources/978-0-8261-1094-7|<bdi>978-0-8261-1094-7</bdi>]]. Retrieved 23 April 2012.</ref>


Mirtazapine was developed in the Netherlands and introduced in the United States in 1996.<ref> "REMERON (mirtazapine) tablet, film coated [Organon Pharmaceuticals USA]". DailyMed. Organon Pharmaceuticals USA. October 2012. Retrieved 24 October 2013.</ref> Its patent expired in 2004 and generic versions have been widely available since.<ref name="Schatzberg">{{cite book | vauthors=((Schatzberg, A. F.)), ((Cole, J. O.)), ((DeBattista, C.)) | date= 2010 | title=Manual of clinical psychopharmacology | publisher=American Psychiatric Pub | volume=3 | edition=7th ed | isbn=9781585623778}}</ref> It is used primarily in the treatment of major depressive disorder and other mood disorders.<ref>{{cite journal | vauthors=((Gorman, J. M.)) | journal=The Journal of Clinical Psychiatry | title=Mirtazapine: clinical overview | volume=60 Suppl 17 | pages=9–13; discussion 46-48 | date= 1999 | issn=0160-6689}}</ref><ref>{{cite journal | journal=Expert Opinion on Pharmacotherapy | title=Review of the use of mirtazapine in the treatment of depression | url=https://informahealthcare.com/doi/abs/10.1517/14656566.2011.585459}}</ref> It has also been prescribed off-label for the treatment of  
Mirtazapine was developed in the Netherlands and introduced in the United States in 1996.<ref> "REMERON (mirtazapine) tablet, film coated [Organon Pharmaceuticals USA]". DailyMed. Organon Pharmaceuticals USA. October 2012. Retrieved 24 October 2013.</ref> Its patent expired in 2004 and generic versions have been widely available since.<ref name="Schatzberg">{{cite book | vauthors=((Schatzberg, A. F.)), ((Cole, J. O.)), ((DeBattista, C.)) | date= 2010 | title=Manual of clinical psychopharmacology | publisher=American Psychiatric Pub | volume=3 | edition=7th ed | isbn=9781585623778}}</ref> It is used primarily in the treatment of major depressive disorder and other mood disorders.<ref>{{cite journal | vauthors=((Gorman, J. M.)) | journal=The Journal of Clinical Psychiatry | title=Mirtazapine: clinical overview | volume=60 Suppl 17 | pages=9–13; discussion 46-48 | date= 1999 | issn=0160-6689}}</ref><ref>{{cite journal | journal=Expert Opinion on Pharmacotherapy | title=Review of the use of mirtazapine in the treatment of depression | url=https://informahealthcare.com/doi/abs/10.1517/14656566.2011.585459}}</ref> It has also been prescribed off-label for the treatment of  
Line 18: Line 18:


==Pharmacology==
==Pharmacology==
Mirtazapine acts as an [[antagonist]]/inverse agonist upon the following receptors:<ref name="Fernandez2005">{{cite journal | vauthors=((Fernández, J.)), ((Alonso, J. M.)), ((Andrés, J. I.)), ((Cid, J. M.)), ((Díaz, A.)), ((Iturrino, L.)), ((Gil, P.)), ((Megens, A.)), ((Sipido, V. K.)), ((Trabanco, A. A.)) | journal=Journal of Medicinal Chemistry | title=Discovery of New Tetracyclic Tetrahydrofuran Derivatives as Potential Broad-Spectrum Psychotropic Agents | volume=48 | issue=6 | pages=1709–1712 | date=1 March 2005 | url=https://pubs.acs.org/doi/10.1021/jm049632c | issn=0022-2623 | doi=10.1021/jm049632c}}</ref><ref>{{cite journal | vauthors=((Boer, Th. de)), ((Maura, G.)), ((Raiteri, M.)), ((Vos, C. J. de)), ((Wieringa, J.)), ((Pinder, R. M.)) | journal=Neuropharmacology | title=Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, org 3770 and its enantiomers | volume=27 | issue=4 | pages=399–408 | date=1 April 1988 | url=https://www.sciencedirect.com/science/article/pii/0028390888901499 | issn=0028-3908 | doi=10.1016/0028-3908(88)90149-9}}</ref>
Mirtazapine inhibits presynaptic serotonin (5-HT)-2 and alpha-2 adrenergic auto- and hetero-receptors, thereby increasing serotonergic and noradrenergic neurotransmission. The increased amount of 5-HT released interacts with postsynaptic 5-HT1 receptors, which may be relevant to the antidepressant effects of the drug. The affinity of mirtazapine for central alpha-2 adrenoreceptors is 10 times higher than for peripheral receptors, resulting in fewer peripheral effects related to increased blood pressure. Mirtazapine is an antagonist at postsynaptic 5-HT2A, 5-HT2C, and 5-HT3 receptors. The blockade of these receptors may result in a lower incidence of certain adverse effects (e.g., anxiety, insomnia, nausea) than occurs with antidepressants that do not antagonize these receptors. Mirtazapine significantly antagonizes histamine H1 receptors at low doses, and this activity is associated with sedation and appetite stimulation. Higher doses have a greater effect on norepinephrine release relative to antihistamine effects, which may offset the sedative potential and appetite stimulation observed at low doses. Mirtazapine has muscarinic antagonist properties, which may be associated with xerostomia, constipation, and other anticholinergic effects. Orthostatic hypotension is the result of the peripheral alpha-1 adrenergic antagonism of the drug. Mirtazapine does not have clinically significant receptor affinity for dopamine, 5-HT1A, or 5-HT1B, and has no effects on the central reuptake of either norepinephrine or serotonin.:<ref name="Fernandez2005">{{cite journal | vauthors=((Fernández, J.)), ((Alonso, J. M.)), ((Andrés, J. I.)), ((Cid, J. M.)), ((Díaz, A.)), ((Iturrino, L.)), ((Gil, P.)), ((Megens, A.)), ((Sipido, V. K.)), ((Trabanco, A. A.)) | journal=Journal of Medicinal Chemistry | title=Discovery of New Tetracyclic Tetrahydrofuran Derivatives as Potential Broad-Spectrum Psychotropic Agents | volume=48 | issue=6 | pages=1709–1712 | date=1 March 2005 | url=https://pubs.acs.org/doi/10.1021/jm049632c | issn=0022-2623 | doi=10.1021/jm049632c}}</ref><ref>{{cite journal | vauthors=((Boer, Th. de)), ((Maura, G.)), ((Raiteri, M.)), ((Vos, C. J. de)), ((Wieringa, J.)), ((Pinder, R. M.)) | journal=Neuropharmacology | title=Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, org 3770 and its enantiomers | volume=27 | issue=4 | pages=399–408 | date=1 April 1988 | url=https://www.sciencedirect.com/science/article/pii/0028390888901499 | issn=0028-3908 | doi=10.1016/0028-3908(88)90149-9}}</ref>


*[[serotonin|5-HT<sub>2A</sub> receptor]]<ref name="Fernandez2005" />
*[[serotonin|5-HT<sub>2A</sub> receptor]]<ref name="Fernandez2005" />
Line 50: Line 50:


{{Preamble/SubjectiveEffects}}
{{Preamble/SubjectiveEffects}}
{{effects/base
{{effects/base
|{{effects/physical|
|{{effects/physical|
Line 64: Line 63:
*'''[[Effect::Bronchodilation]]''' - This can cause swallowing to be extremely difficult and uncomfortable, as with some other [[deliriants|anticholinergics]] such as [[diphenhydramine]]. As with [[diphenhydramine]], it is most prominent during the onset phase of the experience and often fades away as the peak sets in.
*'''[[Effect::Bronchodilation]]''' - This can cause swallowing to be extremely difficult and uncomfortable, as with some other [[deliriants|anticholinergics]] such as [[diphenhydramine]]. As with [[diphenhydramine]], it is most prominent during the onset phase of the experience and often fades away as the peak sets in.
*'''[[Effect::Muscle relaxation]]'''
*'''[[Effect::Muscle relaxation]]'''
*'''[[Effect::Restless legs]]''' - This effect is considered slightly less apparent than it is with [[diphenhydramine]] but more apparent than other atypical antidepressants like Trazadone or Doxepin.
*'''[[Effect::Restless legs]]''' - This effect is considered slightly less apparent than it is with [[diphenhydramine]].
*'''[[Effect::Nausea suppression]]'''
*'''[[Effect::Nausea suppression]]'''
}}
}}
Line 164: Line 163:
*[http://www.erowid.org/pharms/mirtazapine/mirtazapine.shtml Mirtazapine (Erowid Vault)]
*[http://www.erowid.org/pharms/mirtazapine/mirtazapine.shtml Mirtazapine (Erowid Vault)]
*[https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=9430 Mirtazapine (Isomer Design)]
*[https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=9430 Mirtazapine (Isomer Design)]
*[https://go.drugbank.com/drugs/DB00370 Mirtazapine (DrugBank)]
*[http://www.drugs.com/mirtazapine.html Mirtazapine (Drugs.com)]
*[http://www.drugs.com/mirtazapine.html Mirtazapine (Drugs.com)]


Retrieved from "http://psy.st/wiki/Mirtazapine"